Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/12/2025

Treatment of Hypertriglyceridemia

Classification and Risk Assessment

  • The American College of Cardiology recommends that hypertriglyceridemia severity determines treatment urgency, with severe hypertriglyceridemia (≥500 mg/dL) requiring immediate intervention to prevent acute pancreatitis 1, 2
  • Hypertriglyceridemia is classified into different severity levels, including normal (<150 mg/dL), mild (150-199 mg/dL), moderate (200-499 mg/dL), severe (500-999 mg/dL), and very severe (≥1,000 mg/dL), with corresponding treatment approaches 1, 2, 3, 4

Lifestyle Interventions

  • The American College of Cardiology recommends a target 5-10% body weight reduction, which produces a 20% decrease in triglycerides, as the single most effective lifestyle intervention 2, 3
  • Engage in ≥150 minutes/week of moderate-intensity aerobic activity (or 75 minutes/week vigorous activity), which reduces triglycerides by approximately 11% 2, 3
  • Restrict added sugars to <6% of total daily calories, limit total fat to 30-35% of total daily calories, and restrict saturated fats to <7% of total calories for mild to moderate hypertriglyceridemia (150-499 mg/dL) 2, 3
  • Eliminate trans fats completely for all patients with hypertriglyceridemia 1

Pharmacologic Therapy Algorithm

  • The American College of Cardiology recommends initiating fenofibrate 54-160 mg daily immediately as first-line therapy for severe to very severe hypertriglyceridemia (≥500 mg/dL) to prevent acute pancreatitis 1, 2
  • For moderate hypertriglyceridemia (200-499 mg/dL), initiate or intensify statin therapy if LDL-C is elevated or 10-year ASCVD risk is ≥7.5%, and consider adding prescription omega-3 fatty acids (icosapent ethyl 2-4g/day) if triglycerides remain >200 mg/dL after 3 months of optimized lifestyle modifications and maximally tolerated statin therapy 1, 2
  • For mild hypertriglyceridemia (150-199 mg/dL), consider initiating moderate-intensity statin therapy for patients with 10-year ASCVD risk ≥7.5% or persistently elevated nonfasting triglycerides ≥175 mg/dL 2

Special Considerations

  • Icosapent ethyl (prescription EPA) is specifically indicated as adjunct to maximally tolerated statin therapy for patients with triglycerides ≥150 mg/dL and established cardiovascular disease OR diabetes with ≥2 additional risk factors, based on the REDUCE-IT trial showing 25% reduction in major adverse cardiovascular events 1, 2
  • Monitor for increased risk of atrial fibrillation with prescription omega-3 fatty acids 2
  • When combining fenofibrate with statins, use lower statin doses to minimize myopathy risk, particularly in patients >65 years or with renal disease 2, 4

REFERENCES

2

Hypertriglyceridemia Management [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3

Treatment of Hypertriglyceridemia [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

Treatment of Hypertriglyceridemia [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025